References
- Goldman J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Status in 2007. Bone Marrow Transplant 2008; 42(Suppl 1): S11—S13.
- Ruiz-Argiielles GJ, Gömez-Almaguer D, Morales-Toquero A et al.The early referral for reduced-intensity stem cell transplantation in patients with Phl ( +) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043–1047.
- Ruiz-Argiielles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML et al. Therapeutic choices in patients with Phi (+) chronic myelogenous leukemia living in Mexico in the tyrosine kinase inhibitors (TKI) era: stem cell transplantation or TKI's? Bone Marrow Transplant 2008; 42: 23–28.
- Ruiz-Arguelles GJ, Gómez-Almaguer D, Ruiz-Arguelles A, Gonzalez-Llano O, Candi OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66: 241–244.
- Ruiz-Argiielles GJ, Gomez-Almaguer D, Lopez-Martinez B, Cantn-Rodriguez OG, Jaime-Pérez JC, Gonzalez-Llano O. Results of an allogeneic non-myeloablative stem cell transplanta-tion program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894–896.
- Ruiz-Arguelles GJ, Gomez-Almaguer D. Making allogeneic bone marrow transplantation available to patients in developing countries: the Mexican Experience. Open Hematol J2008; 2: 30–36.
- Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua, Frauendorfer K. Hematopoietic stem cell trans-plants for chronic myeloid leukemia in Europe. Impact of cost considerations. Leukemia 2007; 21: 383–386.
- Giralt SA, Arora M, Goldman JM et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.
- Gratwohl A, Brand R, Apperley J et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplanta-tion for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.
- Gratwohl A, Baldomero H, Labar B, Apperley J, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation en Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J 2004; 45: 689–694.
- Gajewski JL, Robinson P. Do affluent societies have the only option for the best therapy? Leukemia 2007; 21: 387–388.
- Moynihan R. Key opinion leaders: Independent experts or drug representative in disguise? Brit Med J 2008; 336: 1402–1403.
- Sox HC, Rennie D. Seeding trials: just say no. Ann Intern Med 2008; 149: 279–280.
- Ruiz-Arguelles GJ, Gomez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L. Multiple myeloma in Mexico: a single institution, twenty-year experience. Arch Med Res 2004; 35: 163–167.
- Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.
- Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484–489.
- López-Otero A, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. A simpli-fied method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant 2009; 44(11): 715–719.
- Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995; 272: 38–47.
- Vela-Ojeda J, Garcia-Ruiz-Esparza MA, Padilla-Gonzalez Y et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Ann Hematol 2007; 86: 277–282.
- Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044–1048.